Keyphrases
Type 1 Diabetes Mellitus (T1DM)
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Pembrolizumab
100%
Overall Survival
42%
Metastatic Non-small Cell Lung Cancer
42%
Non-small Cell Lung Cancer Patients
42%
Chemotherapy
28%
Confidence Interval
28%
Hazard Ratio
28%
Diabetic Patients
28%
Medical Records
14%
Maccabi Healthcare Services
14%
Multivariate Analysis
14%
Independent Risk Factors
14%
Tertiary Care Hospital
14%
Diabetic
14%
Patients with Diabetes Mellitus
14%
Non-diabetic
14%
Health Care Services
14%
Progression-free Survival
14%
Validation Cohort
14%
Immune Dysfunction
14%
Median Progression-free Survival
14%
First-line Pembrolizumab
14%
Chronic Metabolic Disorder
14%
Nursing and Health Professions
Diabetes Mellitus
100%
Lung Cancer
100%
Pembrolizumab
100%
Overall Survival
27%
Confidence Interval
18%
Hazard Ratio
18%
Progression Free Survival
18%
Immunotherapy
18%
Health Care
18%
Patient with Diabetes
9%
Medical Record
9%
Malignant Neoplasm
9%
Multivariate Analysis
9%
Metabolic Disorder
9%
Medicine and Dentistry
Diabetes Mellitus
100%
Lung Cancer
100%
Pembrolizumab
100%
Overall Survival
27%
Hazard Ratio
18%
Immunotherapy
18%
Progression Free Survival
18%
Malignant Neoplasm
9%
Patient with Diabetes
9%
Medical Record
9%
Multivariate Analysis
9%
Health Service
9%
Water-Electrolyte Imbalance
9%
Immune Disorder
9%
Neuroscience
Diabetes Mellitus
100%
Lambrolizumab
100%
Immunotherapy
18%
Metabolic Disorder
9%
Immune System Disorders
9%